“Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation” addresses an increasingly challenge: strong evidence and guideline recommendations do not necessarily translate into timely and equitable access for patients. 🎯PSMA PET/CT has transformed prostate cancer imaging. However, access remains heterogeneous across countries, regions and institutions, with barriers including reimbursement, nuclear medicine capacity, radiopharmaceutical logistics, waiting times and variable referral pathways. 🇪🇺 Exploratory European data suggest that real-world use remains below the estimated eligible population, highlighting an implementation gap between evidence, recommendations and clinical practice. 🎯 Priorities for implementation include guideline-based eligibility, harmonised reimbursement, regional referral networks, adequate imaging and reporting capacity, multidisciplinary collaboration, and measurable access indicators. The next challenge for PSMA PET/CT is not proving its value, but ensuring that eligible patients can access the right imaging at the right time, regardless of geography or institution. #ProstateCancer #PSMAPET #Urology link.springer.com/article/10… @MRoupret @wjurol @InfoAeu @UrologiaClinico